| |
|
|
|
|
|
Company List
Presenting Companies
Company List
| |
|
|
|
| Financial & Investment
Companies: |
|
|
|
| AIG Global Investment Corp |
|
|
|
| AmerAsia Capital Partners |
|
|
|
| American Stock Exchange |
|
|
|
| AXIOM CAPITAL LTD |
|
|
|
| Balyasny Asset Management |
|
|
|
| BayStar Capital |
|
|
|
| BioAsia Investments, LLC |
|
|
|
| BioVeda Capital |
|
|
|
| BioPharma Capital |
|
|
|
| Blue Ridge Capital |
|
|
|
| Caxton Associates |
|
|
|
| China HealthCare Holdings Limited |
|
|
|
| Dassani & Tan LLC |
|
|
|
| DCF Capital, LLC |
|
|
|
| EEK |
|
|
|
| Endpoint Late Stage Fund L.P. |
|
|
|
| Endpointt Late Stage Fund |
|
|
|
| Fountainhead Asset Mgmt |
|
|
|
| HBM Partners |
|
|
|
| HT Pharma |
|
|
|
| Ibis Mgmt |
|
|
|
| Jennison Associates LLC |
|
|
|
| Lone Pine Capital |
|
|
|
| Marincorp Capital LLC |
|
|
|
| Mehta Partners |
|
|
|
| Merrill Lynch & Co., Inc. |
|
|
|
| Northeast Securities Inc |
|
|
|
| Paramount BioCapital, Inc. |
|
|
|
| Passport Capital, LLC |
|
|
|
| Perry Capital |
|
|
|
| Perseus Soros Fund |
|
|
|
| Perseus-Soros Biopharmaceutical Fund |
|
|
|
| Rho Capital Partners, Inc. |
|
|
|
| Rodman & Renshaw LLC |
|
|
|
| rodman and renshaw |
|
|
|
| Rothschild |
|
|
|
| SG Capital Partners, LLC |
|
|
|
| Spencer Clarke LLC |
|
|
|
| TCR |
|
|
|
| The American Stock Exchange, LLC |
|
|
|
| Times Square Capital Management, Inc. |
|
|
|
| Toucan Capital Corp. |
|
|
|
| TSG Partners |
|
|
|
| Warner Technology & Investment Corp |
|
|
|
| William D. Witter, Inc. |
|
|
|
|
|
|
|
| Law
Firms : |
|
|
|
| Foley & Lardner, LLP |
|
|
|
| Greenberg Traurig LLP |
|
|
|
| Jun He Law Offices, LLC |
|
|
|
| Langley Management, LLC |
|
|
|
| Reed Smith LLP |
|
|
|
| Torys LLP |
|
|
|
|
|
|
|
| Management Consultants:
|
|
|
|
| 2Value |
|
|
|
| A.T. Kearney, Inc. |
|
|
|
| Access Worldwide Communications, Inc. |
|
|
|
| BioForesight, Inc. |
|
|
|
| Boston Consulting Group |
|
|
|
| DefinedHealth |
|
|
|
| Dynamica Group, LLC |
|
|
|
| Euro RSCG |
|
|
|
| Excite Media Group LLC |
|
|
|
| Feinstein Kean Healthcare |
|
|
|
| Healthways Communications, Inc. |
|
|
|
| PricewaterhouseCoopers |
|
|
|
| The Anne McBride Company |
|
|
|
| The Trout Group |
|
|
|
|
|
|
|
| Pharmaceutical Companies
: |
|
|
|
| Abrika Pharmaceuticals |
|
|
|
| Aventis Pasteur |
|
|
|
| Axonyx, Inc. |
|
|
|
| Beijing Tri-prime Genetic Engineering Co.,
Ltd |
|
|
|
| BioMarker Pharmaceuticals, Inc. |
|
|
|
| Bridge Pharmaceuticals |
|
|
|
| Bristol-Myers Squibb Company |
|
|
|
| CapitalBio Corporation |
|
|
|
| Celsion Corporation |
|
|
|
| China Worldbest Group Co., Ltd. |
|
|
|
| Chipscreen Biosciences, Ltd |
|
|
|
| Clingenix Beijing |
|
|
|
| CombinatoRx |
|
|
|
| Crimson Pharmaceutical USA |
|
|
|
| Eli Lilly Asia, Inc. |
|
|
|
| Genaissance Pharmaceuticals |
|
|
|
| Gene Clone Co. |
|
|
|
| Genta Inc. |
|
|
|
| Goldengate Biopharma LLC |
|
|
|
| GTC Biotherapeutics, Inc. |
|
|
|
| Hoffmann-La Roche Inc. |
|
|
|
| ImClone Systems Incorporated |
|
|
|
| Indochina Healthcare Ltd |
|
|
|
| Inyx, Inc. |
|
|
|
| Merck & Co., Inc. |
|
|
|
| NAXCOR, INC |
|
|
|
| NexMed (USA), Inc. |
|
|
|
| Pfizer Inc. |
|
|
|
| Pharmaceutical Sourcing Partners Inc. |
|
|
|
| Proctor & Gamble Pharmaceuticals |
|
|
|
| Purdue Pharma L.P. |
|
|
|
| Roche Holding AG |
|
|
|
| Roche R&D Center Shanghai, China |
|
|
|
| Sigma-Tau Research, Inc. |
|
|
|
| Tanox, Inc. |
|
|
|
| Tissera |
|
|
|
| Vion Pharmaceuticals, Inc. |
|
|
|
|
|
|
|
| Media And Others:
|
|
|
|
| Columbia University |
|
|
|
| Discover New York with Kitt Garrett, Inc. |
|
|
|
| National Foundation for Cancer Research |
|
|
|
| NY Post |
|
|
|
| Pacific College of Oriental Medicine |
|
|
|
| Sloan-Kettering Institute |
|
|
|
| Wall Street Reporter Magazine Inc. |
|
|
|
| World Journal |
|
|
|
|
|
|
|
|
Presenting Company Details:
BayHelix Group
(http://www.bayhelix.org/)
BayHelix is an invitation-only, non-profit organization
for leaders of Chinese
origin in the global life
sciences and healthcare community:
To shape the
growth of the life sciences and healthcare industry
around the Pacific Rim and beyond;
To foster and
create business opportunities;
To supply and nurture
the leaders for the community; and
To network and
share information and experience. BayHelix is a
co-organizer of this conference.
Beijing Tri-prime Genetic Engineering Co., Ltd
(http://www.triprime.com/)
Beijing Tri-Prime Genetic Engineering Co., Ltd. (Tri-Prime Gene) is a modern, high-tech, biomedical enterprise, engaged in the R & D, production and commercialization of biomedical products and technology, including genetically engineered medicines, vaccines and diagnostic reagents, as well as the related technology, trade and technical services. In May 1999, Tri-Prime Gene's production line received the national GMP certification for it's main product, "Hapgen", a State Class A medicine authorized by the State Drug Administration (SDA), which is effective in the treatment of many kinds of viruses and malignant tumors. "Hapgen" is a recombinant interferon a1b cloned from healthy Chinese people by Professor Hou Yunde, vice president of the China Academy of Engineering and former president of Tri-Prime Gene.
Tri-Prime Gene has a competitive R&D elite engaged in new product research and development. The National Post-doctoral Scientific Research Center has been set up within Tri-Prime Gene, and maintains connections with many other outstanding research organizations through the 'Post Doc' exchange program. The R & D team concentrates on new product development to maintain the company's competitive position in the market.
|
BioAsia Investments, LLC
(http://www.bioasia.com)
BioAsia Investments, LLC provides funding and strategic advice to life sciences companies. The firm manages the Biotechnology Development Funds, which invests primarily in US companies with late stage products and/or platform technologies. Also, BioAsia assists these companies in the development and commercialization of their products in Asia.
|
Bioveda Capital
(http://www.biovedavc.com/pages/1/index.htm)
BioVeda provides venture capital financing to companies
in the life
sciences with leading proprietary technologies,
and outstanding
scientific and management talent. Being one of only
a handful of
dedicated Asian life science investors, we are also
a crucial business
and scientific bridge between companies in the East
and West, linking
finance and technology between two very diverse
markets.
With offices in both Singapore and the United States,
BioVeda has a
strong combination of broad scientific and medical
expertise, and
financial and investment experience to assist partner
companies.
Bristol-Myers Squibb Company
(http://www.bms.com/)
Bristol-Myers Squibb Company is engaged in the discovery,
development,
licensing, manufacturing, marketing, distribution
and sale of
pharmaceuticals and other healthcare-related products.
The Company has
four business segments: Pharmaceuticals, Oncology
Therapeutics Network
(OTN), Nutritionals and Other Healthcare. The Pharmaceuticals
segment is
made up of the global pharmaceutical and international
(excluding Japan)
consumer medicines business. The OTN segment provides
oncology products,
supportive care products and related supplies to
office-based oncologists
in the United States. The Nutritionals segment consists
of Mead Johnson
Nutritionals, primarily an infant formula business.
The Other Healthcare
segment consists of ConvaTec, Medical Imaging and
Consumer Medicines
(North America and Japan) businesses.
Capital Biochip Corp
(http://www.capitalbiochip.com/)
A global leader in biochip technologies dedicated
to systems biology and
drug discovery. By the directives of Vice Premier
Li Lanqing, Tsinghua
Holdings Co., Ltd., along with other three top institutions,
led the
investment to found the Capital Biochip Corp. and
its affiliate, the
National Engineering Research Center for Beijing
Biochip Technology
(NERCBBT), with a total investment of 240 million
RMB. An additional
investment of 136.5 million RMB was raised from
several leading venture
capital firms, bringing the total registered capital
to 376.5 million
RMB.
Currently, scientists and engineers at Capital Biochip
and NERCBBT are
exploring cutting edge technologies in microfluidic
chips, active
microarrays, laboratory-on-chip systems, implantable
chips,
bioinformatics,medical information system software,
nanomaterials,bio-automation and other technologies.
China Healthcare Action Group
China Healthcare Action Group is a Chinese Healthcare
Leaders’ group that
dedicated to improve and influence Chinese Healthcare
policy
Excite Median group is a co-organizer of this conference
China HealthCare Holdings Limited
(http://www.chinahealthcareltd.com/)
China HealthCare Holdings Limited ("CHC") is a recently restructured
company whose shares are listed on the main board of the Hong Kong
stock exchange (Stock Code: 673). CHC is a facilitating partner for
emerging and leading international healthcare companies, products,
technologies, services and capital to gain access to the People's
Republic of China ("PRC") healthcare sector
Chinese National Council for Biotech Development
(http://www.cncbd.org.cn)
CNCBD is a subsidiary of Ministry Of Science and
Technology (MOST) of
Chinese government. For the last twenty years, CNCBD
has been
responsible for making policies, establishing regulations,
promoting new
technologies, and developing strategic vision and
plans for the biotech
industry in China. The scope of the Center includes
biotechnologies
related agriculture, medicine, pharmaceutical, environment,
energy and
other sectors. In addition, the Center also plays
key roles in critical
issues such as biodiversity and biosafety. CNCBD
is responsible for
program management of investments in biotechnology
by Chinese government
agencies. These funding are the primary source of
capital to support the
biotechnology infrastructures and centers of excellence
in China. CNCBD
publishes the Report of China Biotechnology Development
and several other
publications to facilitate information exchange
related to biotech
industry both domestically and internally. The Center
supports the
growth of biotech industry in China and assists
the establishment of
biotechnology industrial R&D parks throughout the
country. The Director
of CNCBD, Mr. Hongguang Wang, is a highly influential
senior government
official with overall responsibility for CNCBD’s
mission and operation.
Chipscreen Biosciences, Ltd
(http://www.chipscreen.com/)
Chipscreen Biosciences Ltd, established on March
21, 2001 in Shenzhen
with initial seed-capital of $5.8 million US dollars
from investors
across Asia, is a drug discovery company specialized
in novel small
molecule therapeutics. Chipscreen has developed
a proprietary chemical
genomics approach to accelerate the discovery of
new medicines from its
collections of natural products, traditional medicines,
and synthetic
chemical libraries. Central to its drug discovery
platform is the
company’s capability of integrating in silico design,
chemistry, unique
parallel multi-targets high throughput screening,
global gene expression
profiling, and informatics to rapidly and effectively
advance the drug
discovery process. As the leading drug discovery
startup company in
China, Chipscreen focuses on lead discovery and
optimization of
transcription modulators for type II diabetes, cancer,
and osteoporosis.
Chipscreen also provides services, including assay
development,
microarray analysis and combinatorial chemistry,
as a part of its drug
discovery collaborations to other pharmaceutical
companies and academic
institutions.
Clingenix, Inc
(http://www.clingenix.com/)
Clingenix, Inc. is a biotechnology company with a unique approach to the efficient discovery, development, and clinical validation of novel molecular diagnostics. The company is developing a proprietary, cost–effective, molecular screen for insulin resistance (IR), a common metabolic abnormality affecting up to 30% of the world’s population. IR appears prior to and is predictive of type II diabetes and related cardiovascular diseases [1]. In particular, adults with IR have up to ten times greater risk of death from cardiovascular disease and are at greater risk from type II diabetes--the leading cause of new cases of blindness in adults[2] , the leading cause of kidney failure and nerve damage[3], and one of the most costly health problems in America where health care and indirect costs run $132 billion annually[4].
Clingenix is applying cutting edge molecular technology and analyses to biological materials and information in a large, clinical, "living database" of well-characterized Asian patients. Using phenotype-derived target identification and validation processes, Clingenix is able to mine this clinically relevant, living database for novel diagnostics and drug targets.
|
Crimson Pharma
(http://www.crimsonpharmatech.com/)
Crimson is a private pharmaceutical company that
acquires, develops and
commercializes innovative therapeutics to address
unmet medical and
economic needs in the Asian market. Crimson focuses
on acquiring the
regional rights to pharmaceutical compounds and
technologies with
significant pre-clinical, clinical or market data,
and adds value by
accelerating their time-to-market through efficient
clinical and
regulatory development in China.
Founded in 2002, Crimson is headquartered in Hong
Kong and also operates
in the United States and China. The Company has
established a brand new,
10,000 square ft. development center in Shanghai
that houses a full
pre-clinical suite with organic synthesis, formulation
development, as
well as analytical and QC release laboratories.
CWGC Group
(http://www.chinaworldbest.com)
CWGC holds 34 subsidiaries and affiliates in China and overseas, including four publicly listed companies (Shanghai WorldBest, Shanghai WorldBest Industry Development, Shanghai WorldBest Pharmaceutical, and Shanghai Pharmaceutical).
CWGC maintains cooperative and joint-venture relationships with several world famous multinationals, including Dupont of America, BASF of Germany, Porcher of France and Radici of Italy. We have invested in, as well as founded, a number of overseas subsidiary enterprises in North America, Europe, West Africa, and throughout Asia.
Overall, CWGC ranks fourth among the largest industrial groups in Shanghai. It is also the fourth largest company in the region in terms of foreign exchange earnings. CWGC has also become China's largest pharmaceutical group, as well as the largest textile group.
In the new century's information age, CWGC continues to evolve by upgrading traditional industries into knowledge-based industries. Life Science is now CWGC's core industry, with top priority given to its research and development.
|
Excite Media Group
(http:www.excitepr.com)
EMG is a leading edge strategic marketing and public
relations firm.
Committed to the success of our clients’ endeavors,
the mission of EMG is
to consistently and rapidly deliver the results
of our clients need, in
their marketing efforts through personalized responsiveness,
intelligent
counsel and uncompromising tenacity. We have represented
clients in a
wide range of verticals including Fashion, Retail,
Technology and
Financial Services.
Building effective marketing and PR campaigns that
build solid brands and
reputations require researched strategic planning,
effective campaign
management and tenacious execution to win converts
and build momentum. We
bring together senior PR and marketing professionals
to design and
execute exceptional campaigns for exceptional results.
Excite Median group is a co-organizer of this conference
GeneScience Pharmaceutical Inc
(http://www.gensci-china.com/english.htm)
GeneScience - a leading chinese biotech company
founded in Changchun,
China by him in Changchun High-tech Development
Zone. In
2002,GeneSciencei's recombinant human growth hormone
(rhGH, Jintropin)
has captured about 67% of China's growth hormone
market.
GeneScience is one of the largest biopharmaceutical
companies in China
now. It has three products on the market and more
than ten products on
the development pipeline.
GeneSciencei's production facility locates in Changchun
High-tech
Development Zone, it covers more than 20,000m2 of
land and has 11,000m2
of floor space. It is one of the largest and finest
equipped
biopharmaceutical production facilities in China.
GH Pharma
HT Pharma
(http://www.htpharma.com)
HT Pharma, is a strategic consulting firm dedicated to
US-China Pharma/Life Science partnership opportunities.
Its principals include veterans of US-China Pharma/Life
science industry and ex Chinese government officials.
Leveraging its deep knowledge base and strong relationship
within US-China Pharma/Life Science industry, HT Pharma helps
US firms to gain market entry in China, and to channel US
investments to Chinese Pharma/Life Science industry. It also
advises Chinese clients on US market entry, strategic partnership,
financing and regulatory issues
HT Pharma is a co-organizer of this US-China Pharma/Life
Science
opportuinity conference.
JunHe Law Office
(http://www.junhe.com/)
Jun He LAW OFFICES is a leading Chinese law firm
specializing in
commercial legal practice with offices in Beijing,
Shanghai, Shenzhen,
Dailian, Haikou and New York. Founded in April 1989,
Jun He was one of
the first private law firms formed in China, and
has been a pioneer in
the re-established Chinese legal profession. We
are the first private law
firm in China to have opened branches in multiple
Chinese cities and
overseas. Since our inception, we have focused upon
representing foreign
clients in business activities throughout China.
We adhere to
internationally recognized rules and standards in
providing legal
services.
Over the past few years, Jun He has been honored
a number of times as one
of the best law firms in China by the Ministry of
Justice of China. With
a team of more than 80 well-trained lawyers, Jun
He is one of the largest
and most established law firms in China. We are
determined to stay at the
forefront of the Chinese legal profession.
Merck & Co., Inc.
(http://www.merck.com/)
Merck & Co., Inc. is a global research-driven pharmaceutical
products
company that discovers, develops, manufactures and
markets a range of
products to improve human and animal health, directly
and through its
joint ventures. The Company's products include therapeutic
and preventive
agents, generally sold by prescription, for the
treatment of human
disorders and animal health supplies. During 2003,
products that
contributed to the year's sales growth were Singulair
for asthma and
seasonal allergic rhinitis, Fosamax for osteoporosis,
Cozaar/Hyzaar for
high blood pressure, Vioxx and Arcoxia for arthritis
and pain, Cancidas
for infections, Cosopt for glaucoma, Proscar for
benign prostate
enlargement, and Maxalt for migraines. Merck & Co.
sells its products
primarily to drug wholesalers and retailers, hospitals,
clinics,
government agencies and managed healthcare providers
such as health
maintenance organizations and other institutions.
Merrill Lynch
(http://www.ml.com/)
Merrill Lynch & Co., Inc. is a holding company that,
through its
subsidiaries and affiliates, provides broker-dealer,
investment banking,
financing, wealth management, advisory, asset management,
insurance,
lending and related products and services on a global
basis. Merrill
Lynch provides these products and services to an
array of clients,
including individual investors, small businesses,
corporations, financial
institutions, governments and government agencies.
The Company's business
activities are grouped into three business segments,
Global Markets and
Investment Banking group (GMI), Global Private Client
(GPC), and Merrill
Lynch Investment Managers (MLIM), and are conducted
through numerous
United States and non-United States subsidiaries
and affiliates.
Novartis AG
(http://www.novartis.com/)
Novartis AG operates in its core businesses of pharmaceuticals and consumer health, which includes generics, over-the-counter (OTC) self-medication, animal health, medical nutrition, infant and baby foods and products, as well as eyecare products. The Company is organized into two divisions, pharmaceuticals and consumer health. In 2002, the consumer health division was reorganized to include the generics, OTC self-medication, animal health, medical nutrition, infant and baby and CIBA Vision business units. In May 2003, Novartis acquired Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Also in May 2003, the Company acquired the incontinence drug Enablex from Pfizer Inc.
|
Pharmaceutical Sourcing Partners, Inc
(Pharmaceutical Sourcing Partners, Inc)
Founded in 2002 by Dr.Peiling Cheng who has over 10-year experience in both the brand name and generic pharmaceutical industry in the USA. Dr. Cheng’s experience ranges from quality management, laboratory analysis, regulatory filing, manufacturing operations and management consulting from Merck, Warner-Lambert and Ciba-Geneva. PSP’s supplier base covers a wide variety of therapeutic categories (anti-infective; hormones steroids; gastric; cardiovascular) from state and privately owned Chinese enterprises. PSP’s clientele includes leading pharmaceutical companies from the US and Europe. PSP provides the most cost effective solutions for the pharmaceutical industry. PSP sources quality bulk pharmaceutical from China by
1) identifying suppliers complying with FDA/EU cGMP requirements.
2) providing technical and regulatory guidance to bring up and maintain suppliers compliance level
3) serving both the suppliers and clients by providing effective project execution tools for the stages from material approval evaluation, scaling up, stability stidy, to FDA/EU approval.
PSP prides itself with sustained creditability and high-level customer satisfaction.
|
Pfizer Inc.
(http://www.pfizer.com/main.html)
Pfizer Inc.is a research-based, global pharmaceutical company.
The Company discovers, develops, manufactures and markets
prescription medicines for humans and animals, as well as many
consumer products. The Company operates in two business segments:
Pharmaceuticals and Consumer Products. The Pharmaceuticals segment
includes prescription pharmaceuticals for treating cardiovascular
diseases, infectious diseases, central nervous system disorders,
diabetes, urogenital conditions, allergies, arthritis and other
disorders; products for livestock and companion animals, and the
manufacture of empty soft-gelatin capsules. The Consumer Products
segment includes self-medications for oral care, upper respiratory
health, eye care, skin care, gastrointestinal health and other products.
In April 2003, the Company merged with Pharmacia Corporation. The
combined operations of the companies enlarges Pfizer's portfolio of
consumer healthcare brands and expands its animal health business.
Rodman Renshaw
(http://www.rodmanandrenshaw.com/)
Rodman & Renshaw, LLC is a privately-held, full-service
investment bank
committed to fostering the long-term success of
emerging growth companies
through capital raising, strategic advice, insightful
research, and the
development of institutional support. Rodman employs
dedicated,
experienced, and talented professionals within its
equity research,
corporate finance, and sales & trading divisions.
Sigma-Tau
(http://www.sigma-tau.com/About/About.asp)
Sigma-Tau is the worldwide leader in carnitine and
metabolic research.
Our products have helped patients around the world
better manage or
recover from some of the world's most rare diseases
and medical
conditions.
Sigma-Tau devotes approximately 20% of its revenues,
both internationally
and within the United States, to fund clinical research
- a rate higher
than the pharmaceutical industry average. In order
to ensure that the
research necessary to treat unmet medical needs
is conducted, Sigma-Tau
funds research in areas that will not necessarily
provide an immediate
return on investment and has funded more than half
of the published
research on carnitine deficiency and the effects
of carnitine
supplementation
Torys LLP
(http://www.haythecurley.com/about/index.html)
Torys LLP is a US-Canadian business law firm with
300 lawyers in New York
and Toronto. We offer a wealth of talent and experience
and seamless
service to clients on both sides of the US-Canada
boarder as well as in
Europe, Asia and Latin America |
|
|
|
|
Platinum Sponsors
Participants
|
|
